Cryo-Cell

Cryo-Cell is a biotechnology company founded in 1989 and headquartered in the United States. It is the world’s first private cord blood bank, having served more than 500,000 parents from 87 countries with their baby’s cord blood and cord tissue stem cells. The company also has a public banking program in partnership with Duke University, providing cord blood for over 600 transplantations and operating cord blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami.

Cryo-Cell’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their baby’s cord blood, and support the advancement of regenerative medicine. The company operates in an FDA-registered, cGMP-cGTP-compliant facility and is licensed in all states requiring licensure. Moreover, it is AABB-accredited as a cord blood facility and the first U.S. (for private use only) cord blood bank to receive FACT accreditation. Additionally, Cryo-Cell is ISO 13485:2003–certified by TÜV, an internationally recognized, quality assessment organization.

Cryo-Cell is a publicly traded company with the stock symbol OTCQB:CCEL. The company's thorough commitment to quality and accreditation, along with its longevity and provision of both private and public banking programs, positions it as a key player in the cord blood and regenerative medicine industry.